Application for approval of vosoritide for treatment of children with achondroplasia (dwarfism) submitted to the European Medicines Agency

Vosoritide is an analogue of C-type Natriuretic Peptide, which initiates intracellular signals that inhibit the overactive FGFR3 pathway to normalise bone growth. The application is based on data from a Phase III study, supported by long-term data from ongoing extension studies.

Biospace Inc.